Eastman Kodak Company Launches Saline For Lab Operators

Biotechnology and life science firms can now purchase pharmaceutical-grade buffers directly through a new online store.

Updated on Oct. 28, 2026 in Healthcare

Eastman Kodak Company Launches Saline For Lab Operators

Live Poll

Do you trust established non-healthcare brands to produce essential medical and pharmaceutical products?

Eastman Kodak Company has launched KODAK Normal Saline, 0.9%, alongside a new online store dedicated to U.S. customers. The product is a pharmaceutical-grade buffer and reagent manufactured in Rochester for laboratory and bioprocessing use.

Why it matters

The move represents a strategic pivot for the Rochester-based manufacturer to serve the life sciences sector directly. By launching a dedicated e-commerce storefront, the company aims to streamline procurement for biotechnology and pharmaceutical operators.

The new 0.9% concentration KODAK Normal Saline is now available through the company's direct-to-customer e-commerce portal. The scope of this launch covers the entire U.S. market, with all manufacturing operations centralized at the facility in Rochester.

The players

Eastman Kodak Company

A legacy manufacturer based in Rochester that is expanding into the life sciences and bioprocessing reagent market.

The details

The product is designed to function as a standardized reagent and buffer, which are critical components in laboratory and bioprocessing workflows. By facilitating direct purchases through its new online storefront, Eastman Kodak Company is removing traditional intermediaries for biotechnology and life science firms that require consistent, high-grade buffers. This approach aims to reduce procurement friction and supply chain variability for research-focused operations.

Wednesday, October 28, 2026: Eastman Kodak Company announced the new product line and online store.

Market Landscape

This move signals a shift by Eastman Kodak Company to align its chemical manufacturing capabilities with the stringent standards required by the life sciences sector. It follows a pattern of legacy industrial firms repositioning their assets to service the high-growth biotechnology and pharmaceutical reagents market.

Operators in the biotechnology and pharmaceutical sectors should evaluate whether this new direct-to-customer channel offers a more reliable supply of 0.9% saline compared to current vendor relationships. Procurement teams should monitor the online store's fulfillment speed and volume capabilities to determine if it scales with larger bioprocessing needs.

The takeaway

The move enables lab managers to bypass typical industrial distributors, potentially reducing lead times for critical buffer supplies. Operators should monitor the initial order fulfillment data to determine if the platform meets the consistent volume requirements of high-throughput lab environments.